➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Baxter
McKesson
Express Scripts
McKinsey

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for LEE011


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for LEE011?

LEE011 is an investigational drug.

There have been 73 clinical trials for LEE011. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Liposarcoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are forty-one US patents protecting this investigational drug and five hundred and twenty-two international patents.

Recent Clinical Trials for LEE011
TitleSponsorPhase
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerNovartis PharmaceuticalsPhase 2
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesNovartis PharmaceuticalsPhase 1
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT StudyNational Cancer Institute (NCI)Phase 2

See all LEE011 clinical trials

Clinical Trial Summary for LEE011

Top disease conditions for LEE011
Top clinical trial sponsors for LEE011

See all LEE011 clinical trials

US Patents for LEE011

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LEE011   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Ribociclib intermediate and preparation method therefor SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (Suzhou, CN)   Start Trial
LEE011   Start Trial Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Androgen receptor mutation Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Pharmaceutical combinations Novartis AG (Basel, CH)   Start Trial
LEE011   Start Trial Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt Crystal Pharmatech Co., Ltd. (Suzhou, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LEE011

Drugname Country Document Number Estimated Expiration Related US Patent
LEE011 Australia 2014348657 2033-11-13   Start Trial
LEE011 Australia 2017245411 2033-11-13   Start Trial
LEE011 Australia 2019246853 2033-11-13   Start Trial
LEE011 Canada 2929181 2033-11-13   Start Trial
LEE011 China 105899232 2033-11-13   Start Trial
LEE011 Eurasian Patent Organization 201690987 2033-11-13   Start Trial
LEE011 European Patent Office 3068435 2033-11-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
McKinsey
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.